FGEN Sep 2024 1.500 put
| Previous close | 0.7600 |
| Open | 0.7500 |
| Bid | 0.5500 |
| Ask | 1.2000 |
| Strike | 1.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.7500 - 0.7700 |
| Contract range | N/A |
| Volume | |
| Open interest | 195 |
GlobeNewswireFibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsBoth FG-3165 and FG-3175 have demonstrated complementary mechanisms of action with PD-1 inhibitors in preclinical studies SAN FRANCISC
- GlobeNewswire
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. “The FDA’s
- GlobeNewswire
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time. Company management will also participate in one-on-one meetings with investors during the conference. A live audio webcast of the event will be available to investors and other i
